Inflammation and Fibrosis Model Evaluation Support
Distinguish acute inflammation, chronic inflammation, tissue injury, repair, and progression into fibrosis, then combine the model, pathology, and biomarkers that match the disease stage and mechanism.
KGAH-ONE works backward from the development question to organize the model, intervention timing, comparator, inflammation and fibrosis readouts, function, pathology, and molecular evaluation, then connects the program with suitable specialized partners.
Do not treat anti-inflammatory and anti-fibrotic activity as the same outcome.
Inflammation may improve while fibrosis remains, or tissue fibrosis may decrease without a corresponding functional improvement. The required model and readouts depend on intervention timing, disease stage, target organ, and mechanism of action.
KGAH-ONE organizes inflammation, tissue injury, repair, fibroblast activation, collagen deposition, and functional change as one disease trajectory, then designs the evidence package needed for the next decision.
Where does the candidate act—on inflammation, tissue injury, fibrosis, or functional decline?
Define the primary point of action and determine where preventive or therapeutic intervention, acute or chronic disease, and tissue or functional endpoints should demonstrate a difference.
Combine disease stage, intervention timing, pathology, molecular, and functional readouts to interpret anti-inflammatory and anti-fibrotic activity separately.
Go beyond whether the program worked and clarify which disease element improved and how dose, timing, or candidate selection should change next.
Four disease elements to separate in evaluation planning
Do not compress inflammation through fibrosis into one result. Identify the disease stage on which the candidate acts.
Inflammatory Response
Consider cytokines, immune-cell infiltration, BALF, myeloperoxidase, and inflammation-related markers.
Tissue Injury
Evaluate histopathology, necrotic area, tubular injury, mucosal injury, or alveolar injury.
Fibrosis and Matrix Deposition
Use Sirius Red / Masson, α-SMA, hydroxyproline, collagen, and fibrogenic gene expression.
Function and Development Decision
Combine lung function, renal function, liver injury, or disease activity with candidate, dose, and Go / No-Go decisions.
Representative application areas and model examples
These examples are based on information that specialized partners have approved for external use. Actual model selection should be based on disease, mechanism, target species, intervention timing, and the development question.
Pulmonary Fibrosis and ILD
Evaluate alveolar injury, inflammation, fibrosis, and impaired lung function.
- Ashcroft score
- Sirius Red / Masson
- Hydroxyproline and α-SMA
- BALF and micro-CT
- Rrs, Ers, Crs, and IC
Renal Fibrosis
Evaluate rapidly progressing tubulointerstitial fibrosis and inflammation.
- Sirius Red-positive area
- α-SMA and hydroxyproline
- Collagen expression
- Macrophage infiltration
- Inflammatory markers
MASH and Metabolic Liver Disease
Evaluate steatosis, inflammation, hepatocellular injury, fibrosis, and metabolic abnormality.
- ALT / AST and metabolic markers
- Steatosis and lobular inflammation
- Ballooning, NAS, and fibrosis stage
- Sirius Red and α-SMA
- Hydroxyproline
Advanced Liver Fibrosis and Cirrhosis
Evaluate progressive fibrosis, bridging fibrosis, and cirrhosis-like pathology.
- Fibrosis stage
- Sirius Red and α-SMA
- Hydroxyproline
- ALT / AST
- Fibrogenic gene expression
Cholestasis and Cholangitis
Evaluate cholestasis, ductular reaction, cholangitis, and cholestatic fibrosis.
- ALP, bilirubin, and ALT / AST
- Ductular reaction
- Sirius Red and α-SMA
- Inflammation
- Histopathology
IBD and Colitis
Evaluate acute inflammation, chronic inflammation, relapse, mucosal injury, and progression toward fibrosis.
- DAI, body weight, and colon length
- Histology score
- Myeloperoxidase
- Cytokines and immune-cell markers
- Fibrosis-related endpoints
Additional inflammatory approaches, including CAIA referenced on the service hub, may be considered according to the development question, required pathology, expertise, and feasibility.
Representative inflammation and fibrosis readouts
Combine tissue change with inflammation, matrix, function, and disease activity.
| Evaluation Axis | Representative Readouts | What They Can Clarify |
|---|---|---|
| Inflammation | Cytokines, immune-cell infiltration, BALF, myeloperoxidase, inflammatory markers | Inflammatory response, immune-cell context, anti-inflammatory activity, and response interpretation |
| Tissue Injury | Histopathology, necrotic area, tubular injury, mucosal injury, Ashcroft score | Location and severity of injury, disease progression, and tissue-protective activity |
| Fibrosis | Sirius Red / Masson, fibrosis stage, positive area, α-SMA, hydroxyproline, collagen | Collagen deposition, fibroblast activation, fibrosis progression or regression, and anti-fibrotic activity |
| Function / Disease Activity | Rrs / Ers / Crs / IC, BUN / creatinine, ALT / AST, DAI, body weight | Connection between tissue and functional improvement, candidate and dose comparison, and next-study conditions |
| Mechanism | Fibrogenic gene expression, PD biomarkers, target-related markers, pathway-related readouts | Point of action, target engagement, response rationale, and need for additional validation |
On smartphones, scroll horizontally to view the complete table.
Connect the model and readouts with the next development decision
The objective is not model execution itself, but clarity on disease stage, candidate differences, and intervention conditions.
Primary Disease Question
Define whether the main point of action is inflammation, injury, repair, fibrosis, or functional decline.
Model and Intervention Timing
Organize acute or chronic disease, preventive or therapeutic intervention, disease stage, groups, and comparators.
Pathology, Molecular, and Function
Combine inflammation, tissue injury, matrix, biomarkers, and functional readouts.
Next Development Decision
Connect the results with candidate ranking, dose, timing, additional validation, Go / No-Go, or next dog and cat studies.
The meaning of “anti-fibrotic” depends on the mechanism.
The model, timing, endpoint, and duration will differ depending on whether fibrosis is reduced indirectly through inflammation control, directly through fibroblast or matrix action, or through regression of established fibrosis.
Representative public track record of a specialized partner
These are externally usable performance statements from SMC Laboratories. KGAH-ONE leads problem definition and coordination design.
Clarify where the candidate acts across inflammation and fibrosis.
Tell us the disease, organ, modality, mechanism of action, candidate stage, intended intervention timing, and current development question. KGAH-ONE can help organize the model, inflammation and fibrosis endpoints, pathology, biomarkers, and specialized partner pathway.
KGAH-ONE is an Animal Health intelligence and partner coordination platform of Kawasaki Global Animal Health, Inc. Specialized inflammation, fibrosis, pathology and nonclinical evaluation support may be provided by partners such as SMC Laboratories, depending on the development question.